Machteld E. Hillen

Machteld E. Hillen

Auto-generated profile, based on publicly available information

Machteld E. Hillen

Department of Neurology, Rutgers New Jersey Medical School, Newark, New Jersey, USA, rutgers.edu

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1996 in Neurology
Verified
Journal Article
Closed access
PDF file
MHMachteld E. Hillen
Machteld E. Hillen
JSJacob I. Sage
Jacob I. Sage
We studied the nature and frequency of nonmotor "off" phenomena in 130 consecutive patients with Parkinson9s disease (PD) with motor fluctuations.Twenty-two patients (17%) experienced nonmotor fluctuations as an end-of-dose phenomenon. Previously unreported, or little appreciated, nonmotor "off" states include sensory dyspnea, nausea, facial flushing, cough, hunger, unilateral limb edema, proximal limb pain, and trigeminal neuralgia-like pain. We attempted treatment modification in 12 of 22 patients; nonmotor "off" symptoms improved in nine of these 12 patients (75%). Recognizing these phenomena will prevent unnecessary tests and treatments. NEUROLOGY 1996;47: 1180-1183

3 August 2011 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
RERania Ga Elenein
Rania Ga Elenein
LSLeroy R Sharer
Leroy R Sharer
SCStuart D Cook
Stuart D Cook
APAndrew R Pachner
Andrew R Pachner
JMJennifer Michaels
Jennifer Michaels
MHMachteld E Hillen
Machteld E Hillen
Marburg’s variant of multiple sclerosis is a rapidly progressive and malignant form of multiple sclerosis (MS) that usually leads to severe disability or death within weeks to months without remission. Few cases have been described in the literature since the original description by Marburg. The classic pathological findings usually include highly destructive zones of extensive demyelination, necrosis with dense cellular infiltrate, and giant reactive astrocytes. We report a case of a 31-year-old woman with Marburg’s variant of MS who, over a period of eight months, became totally disabled, blind, and quadriplegic, with vocal cord paralysis, requiring a tracheostomy. The patient underwent diagnostic stereotactic brain biopsy. Clinical findings, magnetic resonance imaging (MRI), serologic and cerebrospinal fluid (CSF) findings, and neuropathology are discussed. MRI showed extensive white matter involvement in the brain and spinal cord that continuously progressed over time. A diagnostic stereotactic brain biopsy revealed extensive active demyelination with unexpected finding of active vasculitis and fibrinoid necrosis with a vascular inflammatory cell infiltrate, including polymorphonuclear neutrophils and rare eosinophils. Serologic work-up for vasculitis and neuromyelitis optica was unremarkable and the CSF showed only one oligoclonal band (OCB) not present in serum. This is the second case of Marburg’s variant of MS that demonstrated both demyelination and vasculitis. In our case these features were demonstrated simultaneously, even though the demyelination was the predominant pathological finding. Since vasculitis is not a feature of classic MS, these findings pose the question as to whether Marburg’s variant of MS is a true variant or different entity altogether.

1 July 1996 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
MHMachteld E. Hillen
Machteld E. Hillen
MWMary L. Wagner
Mary L. Wagner
JSJacob I. Sage
Jacob I. Sage

1 April 2015 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
MHMachteld E. Hillen
Machteld E. Hillen
SCStuart D. Cook
Stuart D. Cook
ASArun Samanta
Arun Samanta
EGEvan Grant
Evan Grant
JQJames R. Quinless
James R. Quinless
JRJamuna K. Rajasingham
Jamuna K. Rajasingham

1 January 1996 in Neurology
Verified
Journal Article
Closed access
PDF file
MHMachteld E. Hillen
Machteld E. Hillen
JSJacob I. Sage
Jacob I. Sage
The role of specialist care in the emerging managed health delivery system is changing. Most health maintenance organizations (HMOs) are limiting access to specialists because of concerns about cost. Despite the need to control spending, there is optimism that specialists can "prove their worth," presumably by providing a much better outcome even if it means a higher price. To convince payers not to skimp on specialty care, however, we need more data on qualitative improvements in care provided by specialist consultants. [1] Specialists will need to prove their usefulness to generalists acting as gatekeepers of the health delivery system. Can this be done?

1 December 2014 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
VPVineet Punia
Vineet Punia
ADAnjali Dagar
Anjali Dagar
NANitin Agarwal
Nitin Agarwal
WHWenzhuan He
Wenzhuan He
MHMachteld Hillen
Machteld Hillen